ATE250412T1 - Muskarinische antagonisten zur behandlung von presbyopie - Google Patents
Muskarinische antagonisten zur behandlung von presbyopieInfo
- Publication number
- ATE250412T1 ATE250412T1 AT99937295T AT99937295T ATE250412T1 AT E250412 T1 ATE250412 T1 AT E250412T1 AT 99937295 T AT99937295 T AT 99937295T AT 99937295 T AT99937295 T AT 99937295T AT E250412 T1 ATE250412 T1 AT E250412T1
- Authority
- AT
- Austria
- Prior art keywords
- presbyopia
- treatment
- muscarinic antagonists
- cholinergic
- restore
- Prior art date
Links
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 title 1
- 239000003149 muscarinic antagonist Substances 0.000 title 1
- 201000010041 presbyopia Diseases 0.000 title 1
- 230000004308 accommodation Effects 0.000 abstract 1
- 230000001713 cholinergic effect Effects 0.000 abstract 1
- 230000001886 ciliary effect Effects 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 239000000472 muscarinic agonist Substances 0.000 abstract 1
- 230000001734 parasympathetic effect Effects 0.000 abstract 1
- 230000000284 resting effect Effects 0.000 abstract 1
- 230000036977 tonic contraction Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/126,064 US6291466B1 (en) | 1998-07-30 | 1998-07-30 | Cholinergic agents in the treatment of presbyopia |
| PCT/US1999/016260 WO2000006135A2 (en) | 1998-07-30 | 1999-07-22 | Cholinergic agents in the treatment of presbyopia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE250412T1 true ATE250412T1 (de) | 2003-10-15 |
Family
ID=22422802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99937295T ATE250412T1 (de) | 1998-07-30 | 1999-07-22 | Muskarinische antagonisten zur behandlung von presbyopie |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US6291466B1 (de) |
| EP (1) | EP1100480B1 (de) |
| JP (1) | JP2002521429A (de) |
| KR (1) | KR20010079593A (de) |
| CN (1) | CN1157186C (de) |
| AT (1) | ATE250412T1 (de) |
| AU (1) | AU754588B2 (de) |
| BR (1) | BR9912599A (de) |
| CA (1) | CA2339093A1 (de) |
| DE (1) | DE69911620T2 (de) |
| ES (1) | ES2207963T3 (de) |
| WO (1) | WO2000006135A2 (de) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8911496B2 (en) | 2006-07-11 | 2014-12-16 | Refocus Group, Inc. | Scleral prosthesis for treating presbyopia and other eye disorders and related devices and methods |
| EP2046244B1 (de) | 2006-07-11 | 2018-08-01 | Refocus Group, Inc. | Sklerale prothese zur behandlung von altersweitsichtigkeit und anderen augenerkrankungen sowie entsprechende vorrichtungen |
| ATE439863T1 (de) * | 2006-12-18 | 2009-09-15 | Jorge Luis Benozzi | Ophthalmische zusammensetzungen von parasympathischen stimulantia und entzündungshemmer zur verwendung bei der behandlung von presbyopie |
| GB0711151D0 (en) * | 2007-06-11 | 2007-07-18 | Sra Dev Ltd | Switch for use with an ultrasonic surgical tool |
| GB0724558D0 (en) * | 2007-12-15 | 2008-01-30 | Sharma Anant | Optical correction |
| US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| US20100298335A1 (en) * | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and Methods for Ameliorating or Reducing Presbyopia |
| EP2512492A1 (de) * | 2009-12-14 | 2012-10-24 | University of Massachusetts | Verfahren zur hemmung von grauem star und altersweitsichtigkeit |
| TW201247206A (en) * | 2011-04-07 | 2012-12-01 | Sucampo Ag | Method for treating asthenopia |
| WO2013041967A2 (en) | 2011-09-20 | 2013-03-28 | Altavista Instituto De Investigation Medica S.A.S | Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism |
| KR102198622B1 (ko) | 2013-03-14 | 2021-01-05 | 유니버시티 오브 매사추세츠 | 백내장 및 노안을 억제하는 방법 |
| US10307408B2 (en) | 2013-08-28 | 2019-06-04 | Presbyopia Therapies, LLC | Contact lens compositions and methods for the treatment of presbyopia |
| US10064818B2 (en) | 2013-08-28 | 2018-09-04 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
| US9320709B2 (en) | 2013-08-28 | 2016-04-26 | Presbyopia Therapies Llc | Storage stable compositions and methods for the treatment of refractive errors of the eye |
| US9089562B2 (en) | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US9968594B2 (en) | 2013-08-28 | 2018-05-15 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US9833441B2 (en) | 2013-08-28 | 2017-12-05 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US9314427B2 (en) | 2013-08-28 | 2016-04-19 | Presbyopia Therapies Llc | Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye |
| US11179327B2 (en) | 2013-08-28 | 2021-11-23 | Lenz Therapeutics, Inc. | Compositions and methods for the treatment of presbyopia |
| US9844537B2 (en) | 2013-08-28 | 2017-12-19 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US10617763B2 (en) | 2013-08-28 | 2020-04-14 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
| CN106456584A (zh) * | 2014-02-11 | 2017-02-22 | 阿拉西斯医药公司 | 用于矫正老视的药理学眼科用组合物和其施用 |
| JP6835747B2 (ja) | 2015-06-18 | 2021-02-24 | プレスバイオピア・セラピーズ・インコーポレイテッド | 遠見視力の改善および眼の屈折異常の治療のための組成物 |
| WO2017083619A1 (en) | 2015-11-13 | 2017-05-18 | The University Of Massachusetts | Bifunctional molecules containing peg for use in inhibiting cataracts and presbyopia |
| CH711969A2 (it) * | 2015-12-29 | 2017-06-30 | Pinelli Roberto | Composizione per il trattamento della presbiopia. |
| AU2017311636B2 (en) * | 2016-08-19 | 2023-08-10 | Orasis Pharmaceuticals Ltd. | Ophthalmic pharmaceutical compositions and uses relating thereto |
| BR112020009361A2 (pt) * | 2017-11-17 | 2020-10-13 | Cellix Bio Private Limited | composto de fórmula i, composição farmacêutica para tratar um distúrbio ocular ou complicações do mesmo, método de síntese de composto, método de tratamento de um distúrbio ocular ou complicações do mesmo em um indivíduo que precisa do mesmo e uso de um composto |
| DK3681500T3 (da) * | 2018-04-24 | 2022-06-27 | Allergan Inc | Anvendelse af pilocarpinhydrochlorid til behandling af presbyopi |
| US20210369686A1 (en) * | 2018-10-06 | 2021-12-02 | Biotheravision Llc | Ophthalmic preparations of muscarinic agonist and methods of use |
| CN113518620A (zh) | 2018-10-10 | 2021-10-19 | 乐恩姿医药 | 用于治疗老花眼的组合物和方法 |
| US20210251970A1 (en) | 2018-10-10 | 2021-08-19 | Presbyopia Therapies Inc | Compositions and methods for storage stable ophthalmic drugs |
| CN110496215A (zh) * | 2019-08-23 | 2019-11-26 | 中国人民解放军总医院 | 一种治疗老视的水性滴眼液及其制备方法 |
| US20220079922A1 (en) * | 2020-09-11 | 2022-03-17 | Intratus-Nevada, Inc. | Compositions and methods for treating presbyopia, hyperopia, astigmatism, decreased stereopsis, and decreased contrast sensitivity |
| TW202228706A (zh) * | 2020-10-14 | 2022-08-01 | 日商參天製藥股份有限公司 | 穩定之醫藥組合物 |
| US12180206B2 (en) | 2021-11-17 | 2024-12-31 | Lenz Therapeutics Operations, Inc. | Aceclidine derivatives, compositions thereof and methods of use thereof |
| US11648247B1 (en) | 2021-12-16 | 2023-05-16 | Lenz Therapeutics, Inc. | Compositions and methods for the treatment of presbyopia |
| US20230270671A1 (en) | 2022-01-14 | 2023-08-31 | Somerset Therapeutics, Llc | Pharmaceutically stable pilocarpine formulations with substantially reduced buffer content and related methods |
| US11969410B2 (en) | 2022-02-09 | 2024-04-30 | Somerset Therapeutics, Llc | Low pH pilocarpine and brimonidine compound formulations and related methods |
| TW202404607A (zh) * | 2022-03-30 | 2024-02-01 | 日商參天製藥股份有限公司 | 醫藥製劑之滅菌法與包裝體 |
| US12414942B1 (en) | 2024-03-15 | 2025-09-16 | Lenz Therapeutics Operations, Inc. | Compositions, methods, and systems for treating presbyopia |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5166317A (en) * | 1988-10-31 | 1992-11-24 | Houston Biotechnology Incorporated | Neurotrophic factor |
| FR2638970A1 (fr) | 1988-11-16 | 1990-05-18 | Corbiere Jerome | Nouvelles compositions pharmaceutiques agissant sur la presbytie et leur procede d'obtention |
| US5122522A (en) * | 1989-06-21 | 1992-06-16 | The Trustees Of The University Of Pennsylvania | Treatment and control of ocular development |
| DE69033775T2 (de) | 1989-06-21 | 2001-11-15 | Trustees Of The University Of Pennsylvania, Philadelphia | Verwendung eines Muskarinantagonists zur Herstellung eines Medikaments für die Behandlung und Regulierung der Augenentwicklung |
| EP0648118A1 (de) | 1992-07-02 | 1995-04-19 | Telor Ophthalmic Pharmaceuticals, Inc. | Verfahren und produkte zur behandlung von altersweitsichtigkeit |
-
1998
- 1998-07-30 US US09/126,064 patent/US6291466B1/en not_active Expired - Lifetime
-
1999
- 1999-07-22 BR BR9912599-4A patent/BR9912599A/pt not_active IP Right Cessation
- 1999-07-22 CN CNB998090514A patent/CN1157186C/zh not_active Expired - Fee Related
- 1999-07-22 AT AT99937295T patent/ATE250412T1/de not_active IP Right Cessation
- 1999-07-22 CA CA002339093A patent/CA2339093A1/en not_active Abandoned
- 1999-07-22 WO PCT/US1999/016260 patent/WO2000006135A2/en not_active Ceased
- 1999-07-22 ES ES99937295T patent/ES2207963T3/es not_active Expired - Lifetime
- 1999-07-22 EP EP99937295A patent/EP1100480B1/de not_active Expired - Lifetime
- 1999-07-22 JP JP2000561990A patent/JP2002521429A/ja active Pending
- 1999-07-22 DE DE69911620T patent/DE69911620T2/de not_active Expired - Fee Related
- 1999-07-22 KR KR1020017001311A patent/KR20010079593A/ko not_active Ceased
- 1999-07-22 AU AU52160/99A patent/AU754588B2/en not_active Ceased
-
2001
- 2001-04-25 US US09/842,299 patent/US6410544B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE69911620D1 (de) | 2003-10-30 |
| US6410544B1 (en) | 2002-06-25 |
| KR20010079593A (ko) | 2001-08-22 |
| DE69911620T2 (de) | 2004-07-29 |
| ES2207963T3 (es) | 2004-06-01 |
| AU5216099A (en) | 2000-02-21 |
| EP1100480A2 (de) | 2001-05-23 |
| EP1100480B1 (de) | 2003-09-24 |
| HK1035493A1 (en) | 2001-11-30 |
| BR9912599A (pt) | 2001-05-02 |
| CN1157186C (zh) | 2004-07-14 |
| US6291466B1 (en) | 2001-09-18 |
| CN1311670A (zh) | 2001-09-05 |
| JP2002521429A (ja) | 2002-07-16 |
| CA2339093A1 (en) | 2000-02-10 |
| WO2000006135A2 (en) | 2000-02-10 |
| WO2000006135A3 (en) | 2000-03-23 |
| AU754588B2 (en) | 2002-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE250412T1 (de) | Muskarinische antagonisten zur behandlung von presbyopie | |
| ATE207356T1 (de) | Verwendung von tiagabin zur behandlung von schlafstörungen | |
| ATE320803T1 (de) | Verfahren zur behandlung von alzheimerschen krankheit | |
| DE69739792D1 (de) | Verfahren zur Behandlung von Augenerkrankungen | |
| BR0007699A (pt) | Métodos para restaurar e/ou melhorar a acomodação de pseudofaquia | |
| DE69805973D1 (de) | Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase | |
| DE10199020I2 (de) | Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit. | |
| ATE361752T1 (de) | Methoden zur prophylaxe und behandlung von schäden der wahrnehmungshärchenzellen und der cochlearen neuronen | |
| ATE213411T1 (de) | Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen | |
| NZ334063A (en) | use of a combination of a histamine H1 receptor antagonist and a histamine H3 receptor antagonist to treat upper airway allergic responses | |
| MY112973A (en) | Methods for inhibiting vascular smooth muscle cell migration | |
| ATE453402T1 (de) | Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis | |
| ATE304886T1 (de) | Oxazolidinones zur behandlung von augeninfektionen | |
| DE69613041D1 (de) | Verwendung von Erdalkalimetalsalzen in Mitteln zur Behandlung van Augen- oder Augenlidschmerzen oder Dysesthesien | |
| DE59907195D1 (de) | Verfahren zur behandlung von erkrankungen oder störungen des innenohrs | |
| ATE294584T1 (de) | Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz | |
| PT1007093E (pt) | Metodos para o tratamento de desordens atraves da utilizacao de interleucina-9 e seus antagonistas | |
| DE69733557D1 (de) | Endothelin-antagonisten zur behandlung von herzversagen | |
| ATE222768T1 (de) | Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen | |
| EP0329948A3 (de) | Verwendung von Betablockern zur Behandlung der Progression der kindlichen Achsenmyopie | |
| ATE262362T1 (de) | Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung | |
| ATE369143T1 (de) | Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen | |
| NO984196D0 (no) | Fremgangsmåte for behandling av stoffmisbruk | |
| DE69635282D1 (de) | Behandlung der exzessiven aggressivität mit olanzapine | |
| ATE225181T1 (de) | Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |